These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 22673053)

  • 21. A randomized, placebo-controlled proof-of-concept, crossover trial of phenytoin for hydrocortisone-induced declarative memory changes.
    Brown ES; Lu H; Denniston D; Uh J; Thomas BP; Carmody TJ; Auchus RJ; Diaz-Arrastia R; Tamminga C
    J Affect Disord; 2013 Sep; 150(2):551-8. PubMed ID: 23453674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus.
    Gibbs JE; Walker MC; Cock HR
    Epilepsia; 2006 Mar; 47(3):469-78. PubMed ID: 16529608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of levetiracetam on hippocampal kindling in Noda epileptic rats.
    Ishimaru Y; Chiba S; Serikawa T; Sasa M; Inaba H; Tamura Y; Ishimoto T; Takasaki H; Sakamoto K; Yamaguchi K
    Brain Res; 2010 Jan; 1309():104-9. PubMed ID: 19879253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats.
    Margineanu DG; Matagne A; Kaminski RM; Klitgaard H
    Brain Res Bull; 2008 Nov; 77(5):282-5. PubMed ID: 18722515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamic and pharmacokinetic characterization of interactions between levetiracetam and numerous antiepileptic drugs in the mouse maximal electroshock seizure model: an isobolographic analysis.
    Luszczki JJ; Andres MM; Czuczwar P; Cioczek-Czuczwar A; Ratnaraj N; Patsalos PN; Czuczwar SJ
    Epilepsia; 2006 Jan; 47(1):10-20. PubMed ID: 16417526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition by levetiracetam of a non-GABAA receptor-associated epileptiform effect of bicuculline in rat hippocampus.
    Margineanu DG; Wülfert E
    Br J Pharmacol; 1997 Nov; 122(6):1146-50. PubMed ID: 9401779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Levetiracetam.
    Krishna K; Raut AL; Gohel KH; Dave P
    J Assoc Physicians India; 2011 Oct; 59():656-8. PubMed ID: 22479748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection.
    Ueda Y; Doi T; Nagatomo K; Tokumaru J; Takaki M; Willmore LJ
    Brain Res; 2007 Jun; 1151():55-61. PubMed ID: 17408599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
    van Vliet EA; Aronica E; Redeker S; Boer K; Gorter JA
    Epilepsia; 2009 Mar; 50(3):422-33. PubMed ID: 18717715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement of Dream Enactment Behavior Associated With Levetiracetam Treatment in Dementia With Lewy Bodies.
    Batalini F; Avidan A; Moseley BD; Ringman JM
    Alzheimer Dis Assoc Disord; 2016; 30(2):175-7. PubMed ID: 26485499
    [No Abstract]   [Full Text] [Related]  

  • 31. Levetiracetam inhibits interleukin-1 beta inflammatory responses in the hippocampus and piriform cortex of epileptic rats.
    Kim JE; Choi HC; Song HK; Jo SM; Kim DS; Choi SY; Kim YI; Kang TC
    Neurosci Lett; 2010 Mar; 471(2):94-9. PubMed ID: 20080147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specific effect of levetiracetam in experimental human pain models.
    Enggaard TP; Klitgaard NA; Sindrup SH
    Eur J Pain; 2006 Apr; 10(3):193-8. PubMed ID: 15946871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model.
    Gibbs JE; Cock HR
    Epilepsy Res; 2007 Feb; 73(2):208-12. PubMed ID: 17085017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Continuous subcutaneous use of levetiracetam: a retrospective review of tolerability and clinical effects.
    Rémi C; Lorenzl S; Vyhnalek B; Rastorfer K; Feddersen B
    J Pain Palliat Care Pharmacother; 2014 Dec; 28(4):371-7. PubMed ID: 25313924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary efficacy of levetiracetam in monotherapy.
    Ben-Menachem E
    Epileptic Disord; 2003 May; 5 Suppl 1():S51-5. PubMed ID: 12915342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?
    Klitgaard H
    Epilepsia; 2001; 42 Suppl 4():13-8. PubMed ID: 11564119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levetiracetam has a time- and stimulation-dependent effect on synaptic transmission.
    Yang XF; Rothman SM
    Seizure; 2009 Nov; 18(9):615-9. PubMed ID: 19651528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of risperidone on locomotor activity and spatial memory in rats with hippocampal damage.
    Bardgett ME; Baum KT; O'Connell SM; Lee NM; Hon JC
    Neuropharmacology; 2006 Dec; 51(7-8):1156-62. PubMed ID: 16934300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levothyroxin restores hypothyroidism-induced impairment of hippocampus-dependent learning and memory: Behavioral, electrophysiological, and molecular studies.
    Alzoubi KH; Gerges NZ; Aleisa AM; Alkadhi KA
    Hippocampus; 2009 Jan; 19(1):66-78. PubMed ID: 18680156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline.
    Gault VA; Lennox R; Flatt PR
    Diabetes Obes Metab; 2015 Apr; 17(4):403-13. PubMed ID: 25580570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.